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Abstract 
Therapeutic drug management is regularly performed for aminoglycosides in an effort to maximize their 
effectiveness and safety. The ratio of maximum plasma drug concentration to minimum inhibitory 
concentration (Cmax/MIC) has long been regarded as the primary pharmacokinetic/pharmacodynamic 
(PK/PD) index of clinical efficacy for aminoglycosides due to their concentration-dependent killing. In 
this review, however, we discuss why the area under the plasma concentration‒time curve (AUC)/MIC 
ratio may be a more reliable indicator of bacterial killing and clinical efficacy for these agents.  The 
definitive AUC/MIC efficacy targets for aminoglycosides are less clear, unlike those that exist for 
fluoroquinolones.  Evaluation of available literature suggests that an AUC/MIC ratio of 30–50 for 
aminoglycoside therapy may provide optimal outcomes when targeting non–critically ill 
immunocompetent patients with low–bacterial burden gram-negative infections such as urinary tract 
infections, or in patients receiving additional gram-negative therapy with good source control.  
However, an AUC/MIC target of 80–100 may be more prudent when treating patients with 
aminoglycoside monotherapy or in critically ill patients with high–bacterial burden infections, such as 
nosocomial pneumonia.   Reappraisal of current antimicrobial susceptibility breakpoints for 
aminoglycosides against gram-negative bacteria may also be necessary to achieve these AUC/MIC 
targets and ensure that current empiric doses are not grossly suboptimal in critically ill patients. 
Although it has been historically difficult to calculate AUCs in clinical practice, equation-based and 
Bayesian approaches now can be used to estimate the AUC in clinical practice, with limited PK sampling.  
Additional research is needed to better define optimal AUC/MIC targets for efficacy, especially when 
drugs are used in combination, as well as PK/PD targets associated with suppression of resistance. It is 
also important to determine if AUC can predict nephrotoxicity of these agents or whether trough 
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Introduction 
Aminoglycosides are natural antibiotics produced by soil bacteria that were first introduced for 
clinical use in the 1940s as streptomycin and neomycin.
1
 Over the intervening years, several other 
natural and semisynthetic aminoglycosides have been developed including kanamycin (1957), 
gentamicin (1963), tobramycin (1967), amikacin (1976; a semisynthetic derived from kanamycin), and 
plazomicin (2018; a semisynthetic derived from sisomicin). Four compounds—amikacin, gentamicin, 
tobramycin, and plazomicin—are currently approved by the United States Food and Drug Administration 
(FDA) for the treatment of serious infections due to gram-negative or gram-positive bacteria.
2-5
 
Aminoglycosides are active in vitro against both gram-positive and gram-negative pathogens, but for 
many infections, they are primarily recommended for use in combination therapy.  Table 1 provides the 
United States guideline recommendations for the use of legacy aminoglycosides (gentamicin, 
tobramycin, and amikacin) to treat severe Infections.
6-10
Amid concerns about toxicity (particularly irreversible vestibular injury), the use of 
aminoglycosides began to decline in the 1980s in favor of newer antibiotic classes such as 
fluoroquinolones, which were perceived to be less toxic.
  
1
 However, the increasing prevalence of 
multidrug-resistant (MDR) gram-negative pathogens—including carbapenem-resistant 
Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp., for which therapeutic options 
are limited—has led to renewed interest in aminoglycosides for use as monotherapy or typically in 
combination with other antibacterials.
11,12
 Given the reemergence of aminoglycosides as an important 
treatment option for infections caused by MDR gram-negative bacteria, an improved understanding is 
needed of the pharmacokinetic/pharmacodynamic (PK/PD) profile and therapeutic targets of these 
agents. Historically, the ratio of maximum plasma drug concentration to minimum inhibitory 
concentration (Cmax/MIC) has been considered the PK/PD index most closely linked to bacterial killing 
and clinical efficacy for aminoglycosides.
13
 However, support is now increasing for the area under the 
plasma concentration‒time curve (AUC)/MIC ratio as a more accurate measure of exposure-efficacy 
relationships.
14
 In this review, we discuss our updated understanding of the PK/PD profile of 
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for efficacy. We further describe how the AUC can be adopted to guide aminoglycoside dosing in clinical 
practice. Finally, we suggest future directions for research on the PK/PD properties of aminoglycosides. 
Support for the Cmax/MIC Ratio as a PK/PD Index 
Data from in vitro pharmacodynamic infection models and animal studies conducted in the 1980s 
highlighted the importance of the Cmax/MIC ratio and showed that once-daily aminoglycoside dosing 
regimens, in large, had similar efficacy to multiple-daily dosing regimens.
15-19
 Although some early 
animal studies in neutropenic rodents showed less efficacy with once-daily dosing compared with 
multiple-daily dosing, it is important to note that dosing was not humanized in these studies, and the 
differences in response rates were postulated as due to the more rapid elimination of aminoglycosides 
in rodents relative to humans.
20,21
 Best early clinical support for Cmax/MIC as the appropriate PK/PD index 
for aminoglycoside dosing was provided in a 1987 landmark study by Moore and colleagues.
22
Kashuba and colleagues also highlighted the therapeutic importance of the first measured 
Cmax/MIC in their evaluation of 78 patients with nosocomial pneumonia due to gram-negative bacteria 
who were treated with high-dose, extended-interval gentamicin or tobramycin.
 This study 
included data from four earlier clinical trials of gentamicin 2 mg/kg every 8 hours, tobramycin 2 mg/kg 
every 8 hours, and amikacin 8 mg/kg every 8 hours, and examined the association between Cmax and 
clinical response. Plasma samples were taken 1 hour prior to (trough) or 1 hour after (peak) a 30-minute 
infusion, and maintenance doses were adjusted to achieve a Cmax of 5–10 mcg/ml for gentamicin and 
tobramycin, and 20–40 mcg/ml for amikacin. In total, 236 patients treated with aminoglycosides for 
suspected sepsis caused by gram-negative pathogens were included in this pooled analysis. The urinary 
tract and lower respiratory tract were the most common sites of infection (64% and 16%, respectively), 
and 37% of patients had bacteremia. Overall, clinical response was observed in 80% of patients, and the 
maximal (highest value during therapy) Cmax/MIC ratio was strongly associated with clinical response 
after adjustment for underlying severity of illness and other factors correlated with response. More 
important, a graded exposure response was observed with clinical responses of approximately 70%, 
84%, 88%, and 92% when the maximal Cmax/MIC ratios were 4 to < 6, 6 to< 8, 8 to < 10, and ≥ 10, 
respectively.  
23
 In this study, 
attainment of a Cmax/MIC ratio of ≥ 10 was associated with a 90% probability of temperature and white 
blood cell count resolution by day 7 of therapy. The AUC/MIC ratio was also found to be predictive of 
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90% probability of temperature resolution, and a ratio of ≥ 175 was associated with a 90% probability of 
white blood cell count resolution), but statistical analyses showed that the Cmax/MIC ratio was the most 
important predictor of clinical and microbiologic resolution. Although a correlation between the 
Cmax/MIC and AUC/MIC ratios was not reported, it was assumed to be high given that both PK/PD 
parameters reflect concentration-dependent activity. 
Combined, these studies have contributed to the pharmacologic rationale for high-dose, 
extended-interval dosing for patients with gram-negative infections. Although they highlight the 
benefits of achieving a high Cmax/MIC ratio, these studies were not prospectively designed to ascertain 
the optimal PK/PD index. For example, whereas the patients included in the analysis by Moore et al. 
received traditional or multiple daily doses of aminoglycosides,
22
Support for the AUC/MIC Ratio as a PK/PD Index 
 most institutions now use once-daily or 
high-dose, extended-interval dosing for patients with gram-negative infections. Furthermore, this study 
only evaluated one dosing regimen, making it even more difficult to elucidate the key PK/PD efficacy 
driver. 
Although the prevailing wisdom has historically been that the Cmax/MIC ratio is the critical 
exposure target for aminoglycosides, an equivalent body of evidence suggests that the AUC/MIC ratio is 
the PK/PD driver for bacterial killing and efficacy. When attempting to identify the PK/PD index for an 
antibiotic, it is preferable to conduct in vivo or dynamic in vitro PK/PD preclinical model studies rather 
than clinical studies, which have a number of disadvantages for the reasons mentioned earlier. One way 
to separate the collinearity of these measures and identify the PK/PD measure most closely associated 
with efficacy is through the use of dose-escalation and dose-fractionation studies in preclinical PK/PD 
infection models. As stated above, dose-fractionation studies in animals and in vitro PK/PD infection 
models have not demonstrated differences in efficacy between once-daily, multiple-daily, and 
continuous-infusion aminoglycoside dosing regimens,
15-19
 indicating that the PK/PD driver for efficacy is 
better linked to the AUC/MIC ratio than the Cmax/MIC ratio. If the Cmax/MIC ratio was more important 
than the AUC/MIC ratio, then the once-daily regimens would have better efficacy than the multiple-daily 
dosing regimens. The best illustrative example that highlights that the AUC/MIC ratio is the preferred 
PK/PD efficacy driver for aminoglycosides comes from a murine neutropenic thigh model of infection 
with Klebsiella pneumoniae by Craig et al.
13
 In this extensive in vivo investigation that sought to 
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correlated (R
2
=96%) with efficacy (measured by change in colony-forming units [CFU])/g from baseline) 




 Furthermore, as part of 2016 report from the National 
Antimicrobial Susceptibility Testing Committee for the United States (USCAST), data from previous 
neutropenic mouse thigh and lung infections models for gentamicin, tobramycin, and amikacin were 
pooled, and subsequent analyses demonstrated nearly identical relationships between total drug 
plasma AUC0–24/MIC ratio and change in the bacterial density of Enterobacteriaceae after 24 hours of 
therapy for all included aminoglycosides.
14
 Similarly, animal and in vitro models have demonstrated that 
the AUC/MIC ratio is the index that correlates best with efficacy for plazomicin.
24-26




 In a study of 23 patients receiving tobramycin monotherapy for intraabdominal or 
lower respiratory tract infections due to gram-negative pathogens, an AUC0–24/MIC ratio ≥ 110 was 
associated with a significantly higher rate of clinical cure (80% vs 47% for an AUC0–24/MIC ratio < 110, 
p<0.01).
27
 Among 13 patients with cystic fibrosis aged 21 years or younger receiving tobramycin in 
combination with ticarcillin for management of P. aeruginosa infection,
28
 the ratio of fAUC (AUC 
corrected for protein binding) to MIC was significantly correlated (r=0.77, p=0.002) with improvement in 
forced expiratory volume (FEV1). The correlation between fpeak/MIC and FEV1 was also significant 
(r=0.67, p=0.002). The maximum effect was achieved at an fAUC/MIC ratio of around 50 and an 




Practical Considerations for Favoring AUC/MIC Ratio as a PK/PD Index 
Although past evidence illustrates that the Cmax/MIC and AUC/MIC ratios are each predictive of clinical 
outcomes and microbiologic eradication, practical concerns provide reasons to prefer the AUC/MIC ratio 
as the PK/PD index to guide dosing of aminoglycosides. Estimates of Cmax in a single patient can vary 
substantially based on the duration of the infusion and the timing of Cmax sample collection after start of 
dosing, impairing the reliability of this measure. Recommendations and reported practices for obtaining 
the Cmax measure have ranged from a blood sample collected immediately to 30, 60, or even 120 
minutes after a bolus or a 30-, 60-, or 120-minute intravenous infusion.
22,29-32
 A survey of intensive care 
units highlighted the continuing variability in administering aminoglycosides and collecting Cmax 
concentrations.
33
 In this study, the median duration of intravenous infusion was 60 minutes for amikacin 
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The consequences of sampling the Cmax concentrations at different times after start of dosing 
were highlighted in the study by Blaser et al.
32
 In this study, serum concentrations of gentamicin, 
amikacin, and netilmicin from 58 patients were measured immediately after a 30-minute infusion and 
then 90 minutes later (2-hour values). The mean ratios of the 30-minute to 2-hour concentrations were 
2.21 for gentamicin, 2.12 for amikacin, and 2.18 for netilmicin. Thus, a serum concentration measured 
30 minutes after dosing was more than twice as high as one measured 2 hours after dosing. Similarly, 
Demczar and colleagues demonstrated that the distribution phase of aminoglycosides can last between 
1.45 and 2.7 hours after the start of the infusion, depending on the dose infused, and the Cmax can vary 
considerably depending on when the blood sample is collected (30, 60, or 120 minutes) in relationship 
to the dose.
34
 Furthermore, they indicated that sampling during the distribution phase can severely 
overestimate the Cmax. Thus, the potentially large differences in observed concentrations measured over 
the first 2 hours after drug infusion reflect the difficulty in relying on Cmax as an accurate measure of an 
aminoglycoside’s PK/PD profile in a single patient. 
In contrast to the intrapatient variability associated with Cmax, the AUC is a more reliable and 
stable measure. Cmax measures drug exposure at an individual time point, whereas AUC reflects 
cumulative exposure over the entire dosing period. Unlike Cmax, AUC is less sensitive to subtle 
differences in PK concentration collection times. Of note, USCAST used the AUC/MIC ratio for the basis 
of their evaluation of in vitro susceptibility test interpretive criteria for aminoglycosides, given the 




Integration of the AUC/MIC Ratio into Clinical Practice 
Proposed AUC/MIC Ratio Targets 
 
Unfortunately, the definitive AUC/MIC targets for therapy with many aminoglycosides are less 
clear, unlike those that exist for fluoroquinolones.
36
 Evaluation of the literature indicates that AUC/MIC 
ratios typically associated with efficacy of certain aminoglycosides are approximately 30–100 for most 
studies. Mouton et al. demonstrated that an fAUC/MIC ratio of 50 provided maximal benefit when 
treating cystic fibrosis pulmonary infections with tobramycin; however, an important caveat was that all 
patients were also receiving ticarcillin in this study.
28
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50 and 100 were associated with stasis and 1–2-log10 killing, respectively, when evaluating in vitro K. 
pneumoniae neutropenic mice.
13
 This is largely consistent with pooled data analyses in the 2016 USCAST 
report and subsequent presentations that indicated that the AUC/MIC ratio targets required for stasis 
and 1-log10 CFU reduction from baseline were ~30 and ~80, respectively.
14,35,37,38
  Smith et al., as stated 
previously, demonstrated higher clinical cure in patients with AUC0–24/MIC ratios of > 110, irrespective of 
the infecting gram-negative pathogen.
27
 Therefore, based on current literature, an AUC/MIC ratio of 30–
50 for aminoglycoside therapy may provide optimal outcomes when targeting non–critically ill 
immunocompetent patients with low–bacterial burden gram-negative infections such as urinary tract 
infections, or in patients receiving additional gram-negative therapy with good source control. However, 
an AUC/MIC ratio target of 80–100 may be more prudent when treating patients with aminoglycoside 
monotherapy or in critically ill patients with high–bacterial burden infections, such as hospital-acquired 
pneumonia.
38
 Further studies of AUC/MIC based dosing will help refine of the AUC/MIC ratio targets 
need for optimal response. 
 
AUC Alone versus AUC/MIC Ratio–Guided Therapeutic Drug Management for Efficacy 
 
Although the best available evidence suggests that the PK/PD driver for efficacy is the AUC/MIC 
ratio, it may be preferable to use the AUC alone versus the AUC/MIC ratio to optimize aminoglycoside 
dosing. Although the MIC informs the extent of exposure required for efficacy, it is important to 
recognize the inherent imprecision of MIC measurement, with a range of accuracy of ±1log2 dilution and 
the high degree of variability between MIC testing methods. Furthermore, the MIC value is typically not 
available within the first 72 hours of index culture collection, if at all, across most institutions. Notably, 
the South Australian Expert Advisory Group on Antimicrobial Resistance (SAAGAR) has recently issued 
guidance recommending that high-dose, extended-interval aminoglycoside dosing should be guided by 
the AUC, which is more accurately estimated by two sample measurements.
39
 Although the definitive 
target AUC0–24 has not been fully elucidated, AUC0–24 targets of 70–120 mg•hour/L have been proposed 
by some authors for gentamicin.
40,41
 Alternatively, it would be reasonable, pending further data, to 
empirically target AUC/MIC ratios of 30–50 or 80–100, depending on the infection site and severity, until 
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The ability of commonly employed aminoglycoside dosing regimens to achieve these critical 
AUC/MIC ratio targets are best illustrated in the USCAST 2016 report and subsequent 
presentations.
14,35,37,38
 Employing their proposed AUC/MIC ratio targets required for stasis and 1-log10 
CFU reduction from baseline of ~30 and ~80, respectively, the simulations demonstrated that standard 
aminoglycoside regimens failed to achieve these PK/PD exposures for infections with MIC values at or 
near the current Clinical and Laboratory Standards Institute and FDA susceptibility breakpoints for 
gentamicin, tobramycin, and amikacin.
2-4,42
 On the basis of the Monte Carlo simulations and MIC 
distributions among gram-negative bacteria observed in recent surveillance studies, USCAST has 
recommended lowering the susceptibility breakpoints for these aminoglycosides (Table 2
2-4,38,42-44
). 
Alternatively, doses of aminoglycoside that are higher than what is currently recommended would be 
needed to support these breakpoints, although safety data are limited to endorse such an approach at 
this time. 
 
Therapeutic Drug Management for Toxicity 
In addition to maximizing efficacy, one of the goals of therapeutic drug management for 
aminoglycosides is to minimize toxicity in patients.
45,46
 Although there are data suggestive of AUC/MIC 
targets for efficacy, AUC targets for toxicity, in particular for acute kidney injury, are unclear. Previous 
studies have found that the daily aminoglycoside (amikacin, gentamicin, or tobramycin) AUC is a 
predictor of nephrotoxicity in patients with serious bacterial infections.
47,48
 However, the daily and 
cumulative AUC threshold associated with acute kidney injury was primarily described in patients 
receiving traditional, multiple-daily dosing, and the AUC threshold for patients receiving once-daily 
dosing has not been well described. Until such data are available, clinicians should rely on more 
traditional approaches for monitoring drug levels to minimize toxicity. In the SAAGAR guidance 
document on aminoglycoside dosing and monitoring, it is recommended that clinicians aim for a 
gentamicin trough concentration of 0.5–1 µg/ml to minimize toxicity.
39
 A similar trough is assumed for 
tobramycin, although most institutions maintain a laboratory trough set point of below 2 µg/ml to 
minimize toxicity. A specific trough target to minimize toxicity of amikacin is unclear based on a 
systematic review of the literature,
49
 although most institutions recommend a trough below 5 µg/ml. 
For plazomicin, it is recommended that plasma trough concentrations should be maintained below 3 


















This article is protected by copyright. All rights reserved 
 
New Approaches for AUC-Guided Therapeutic Drug Management 
Equation-based and Bayesian approaches can be used to estimate the AUC in clinical practice with 
limited PK sampling.
50,51
 Equation-based approaches rely on simple first-order PK models that allow the 
daily AUC value to be calculated with reasonable accuracy from two concentration levels measured at 
expected peak (1–2 hours postinfusion) and a mid-dosing interval sample (8–12 hours after the start of 
the infusion) for high-dose, extended-interval dosing.
51,52
 Subsequently, the equations can be 
programmed to compute the AUC automatically.
51
 The equation-based approach provides a “real-world 




The Bayesian approach is based on Bayes’ theorem and incorporates information about how a 
drug has behaved in prior patients as well as current PK information from the individual patient.
50,51
 In 
short, the Bayesian approach takes into account the estimated probability distribution of an individual 
patient’s PK parameter values (e.g., volume of distribution or clearance) before administering the drug 
based on the way the drug has behaved in prior patients (Bayesian prior). As dosing and concentration 
data become available, the probability distribution of a given patient’s PK parameter values (Bayesian 
conditional posterior) will be revised. With the Bayesian conditional posterior, the AUC can be estimated 
with low bias and subsequent AUC-optimized dosing recommendations can be provided in real time.
51
 
Software is readily available to implement the Bayesian approach at the patient’s bedside,
51,53,54 
and guidance for adopting this approach for the dosing of gentamicin and tobramycin has been 
published.
40,55,56
 The Bayesian software requires only one or two serum concentrations to accurately 
calculate AUC, can support innovative dosing regimens, does not require waiting until steady state is 
reached to obtain the concentration sample, and can model covariates such as creatinine clearance that 
affect drug PK.
50,51
 Recent studies have provided support for the AUC-guided, Bayesian approach to 
dosing for vancomycin.
57,58
 Compared with trough-based concentration targets, the AUC-guided 
approach was shown to lead to decreased nephrotoxicity, reduced per-patient blood sampling, and 
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Knowledge of PK/PD parameters underlying the efficacy and safety of aminoglycosides has greatly 
expanded in recent years, with an emphasis on the importance of the AUC/MIC ratio as an appropriate 
index for aminoglycoside dosing. Additional research is needed to better define optimal AUC/MIC ratio 
targets for efficacy, especially when drugs are used in combination, as well as PK/PD targets associated 
with suppression of resistance. It is also important to determine if AUC can predict nephrotoxicity of 
these agents, or whether trough concentrations should be used instead. Frequency of monitoring trough 
concentrations (vs calculating the AUC) in patients with less severe infections, and thus having a lower 
risk of PK variability, requires further investigation. Finally, questions remain concerning the best 
methods to calculate AUC (equation-based or Bayesian) or via other software-based methods. 
Conclusion 
Aminoglycosides are useful agents for the treatment of infections caused by MDR gram-negative 
pathogens. Our recent improved understanding of the PK/PD parameters of these agents has helped 
identify appropriate targets for dosing aminoglycosides to ensure exposure to a therapeutic dose while 
minimizing risk of toxicity. The AUC/MIC ratio has emerged as a particularly important guide for optimal 
dosing of these agents. New approaches that can be implemented through readily available software 
tools allow the practitioner to estimate drug exposure for individual patients, with sufficient accuracy to 
meet the appropriate AUC/MIC ratio target. With greater confidence in effective dosing, clinicians can 
add aminoglycosides back into their toolkit to combat MDR pathogens. 
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 and Dose 




If the prevalence of fluoroquinolone 
resistance exceeds 10%, a 
consolidated  




Gentamicin 5–7 mg/kg IV daily 
 




A potential option as combination 
therapy for patients with HAP who 
have a high risk of mortality 
Not stated 
Amikacin 15–20 mg/kg IV daily 
Gentamicin 5–7 mg/kg IV daily 
Tobramycin 5–7 mg/kg IV daily 
Should be avoided in patients with 
VAP if alternative agents with 
adequate gram-negative activity are 
available 
Weak recommendation,  
low-quality evidence 
 
Infectious Diseases Society of 
America: Intravenous Catheter-
As combination therapy for 
bloodstream infection due to 
Enterococcus spp. or Pseudomonas 
Strong recommendation, 
medium-quality evidence 
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Related Infections
8
 aeruginosa Amikacin 15 mg/kg IV daily  
(P. aeruginosa) 
Tobramycin 5–7 mg/kg IV daily (P. 
aeruginosa) 
Surviving Sepsis Campaign 




As combination therapy for sepsis 
and septic shock, except in patients 
with severe renal impairment 
Weak recommendation,  
low-quality evidence 
Gentamicin 5–7 mg/kg IV daily 
 




As combination therapy for 
infective endocarditis caused by 










Gentamicin 3 mg/kg IV or IM in 1 
dose or in 3 equally divided doses 
daily (Streptococcus spp.) 
Gentamicin 3 mg/kg ideal body 
weight daily in 2–3 equally 
divided doses (Enterococcus spp.
b
 
and Staphylococcus spp.) 
HAP = hospital-acquired pneumonia; VAP = ventilator-associated pneumonia. 
a
Amikacin, gentamicin, and tobramycin only; plazomicin was approved in 2018 and is therefore not yet included in these guidelines. 
b
Gentamicin dose should be adjusted to achieve a peak serum concentration of 3–4 μg/ml and trough serum concentration of < 1 μg/ml when 
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Recommended Breakpoint (µg/ml)       
Enterobacteriaceae Pseudomonas spp. Acinetobacter
a 
spp. 
Susceptible Intermediate Resistant Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Amikacin (20–30 mg/kg)       
EUCAST
43
 ≤ 8 16 > 16 ≤ 8 16 > 16 ≤ 8 16 > 16 
CLSI
42
 ≤ 16 32 ≥ 64 ≤ 16 32 ≥ 64 ≤ 16 32 ≥ 64 
FDA
2
 ≤ 16 32 ≥ 64 ≤ 16 32 ≥ 64 ≤ 16 32 ≥ 64 
USCAST
38
 ≤ 4 – ≥ 8 ≤ 2 – ≥ 8 – – – 
Gentamicin (5–7.5 mg/kg)       
EUCAST
43
 ≤ 2 4 > 4 ≤ 4 – > 4 ≤ 4 – > 4 
CLSI
42
 ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 
FDA
3c

























≤ 1 – ≥ 4 – – – – – – 
Tobramycin (5–7.5 mg/kg)       
EUCAST
43
 ≤ 2 4 > 4 ≤ 4 – > 4 ≤ 4 – > 4 
CLSI
42
 ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 
FDA
4










≤ 1 – ≥ 4 – – – – – – 
Plazomicin (15 mg/kg)       
FDA
44
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CLSI = Clinical and Laboratory Standards Institute; EUCAST = European Committee on Antimicrobial Susceptibility Testing; FDA = U.S. Food and 
Drug Administration; USCAST = National Antimicrobial Susceptibility Testing Committee for the United States.
 
a
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Figure 1. The relationship between different pharmacokinetic/pharmacodynamic indices and change in 
the number of bacteria for amikacin in the thighs of neutropenic mice. The R
2
 value reflects the 
coefficient of determination. 
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